GAIN THERAPEUTICS INC
GANXNASDAQTrading Snapshot
- Day Range
- $2.03 – $2.08
- 52-Week Range
- $1.46 – $4.34
- Volume
- $4.12B
- Avg Volume
- $5.01B
- Shares Outstanding
- 42.7M
- Next Earnings
- Sep 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $3M
- P/E Ratio
- -4.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.47
- Dividend Yield
- 0.00%
Why Investors Own GANX
- ✓High-growth profile — revenue up +56.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GAIN THERAPEUTICS INC
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of